Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
CARDENE SR vs AFEDITAB CR
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Nicardipine is a dihydropyridine calcium channel blocker that inhibits the transmembrane influx of calcium ions into vascular smooth muscle and cardiac muscle. It produces relaxation of coronary vascular smooth muscle and dilation of coronary arteries, and also dilates peripheral arteries, reducing systemic vascular resistance and blood pressure.
Nifedipine is a dihydropyridine calcium channel blocker that inhibits the influx of calcium ions through L-type channels in vascular smooth muscle and cardiac muscle, leading to vasodilation and reduced myocardial contractility.
Hypertension,Chronic stable angina
Hypertension,Chronic stable angina,Vasospastic angina (Prinzmetal's angina)
Initial: 30 mg orally twice daily (SR capsules). Titrate up to 60 mg twice daily. Usual maintenance: 30-60 mg twice daily.
30-60 mg orally once daily, extended-release; maximum 90 mg/day.
Terminal elimination half-life 8.6 hours (range 6-15 hours). Clinical context: No accumulation at steady state with TID dosing.
Terminal elimination half-life is 6-11 hours; prolonged in hepatic impairment and elderly due to reduced clearance
Primarily hepatic via cytochrome P450 (CYP3A4) isoenzyme.
Primarily hepatic via CYP3A4; undergoes extensive first-pass metabolism.
Renal: 60% (metabolites, unchanged drug <1%); Biliary/Fecal: 35%
Renal (80% as inactive metabolites), fecal (15% as metabolites), unchanged drug (<1%)
95-98%, primarily to albumin and alpha-1-acid glycoprotein
92-98% bound to plasma proteins (primarily albumin)
0.3-0.7 L/kg. Clinical meaning: Indicates extensive tissue distribution.
0.5-0.9 L/kg; high distribution indicates extensive tissue binding
Oral: 35% (first-pass metabolism); Food does not significantly affect bioavailability.
Oral extended-release: approximately 50-60% due to first-pass metabolism; absolute bioavailability is 45-60%
No specific GFR-based dose adjustment provided by manufacturer; use with caution in renal impairment, especially if concurrent hepatic impairment.
No adjustment required for any degree of renal impairment, but use with caution in patients with severe renal failure due to risk of hypotension.
Child-Pugh Class A: No adjustment. Child-Pugh Class B/C: Consider starting at 15 mg twice daily and titrate slowly due to increased bioavailability.
Child-Pugh A: no adjustment; Child-Pugh B: reduce dose by 50%; Child-Pugh C: contraindicated.
Not established; safety and efficacy in pediatric patients have not been determined.
Not recommended for use in pediatric patients; safety and efficacy not established.
Start at lower initial dose (15 mg twice daily) and titrate cautiously due to increased bioavailability and slower elimination.
Initiate at lower end of dosing range (30 mg once daily) due to increased sensitivity to hypotensive effects and potential for reduced hepatic clearance.
None.
No FDA black box warning.
Use caution in patients with coronary artery disease; may cause increased angina or acute myocardial infarction upon initiation or dose titration. Also caution in patients with congestive heart failure, hepatic impairment, or renal impairment. Monitor blood pressure during titration.
Hypotension, especially with immediate-release formulations,Peripheral edema,Hepatic impairment,Increased angina/acute MI upon withdrawal or dose escalation,Beta-blocker withdrawal,Congestive heart failure
Hypersensitivity to nicardipine or any component; advanced aortic stenosis.
Hypersensitivity to nifedipine or any component,Cardiogenic shock,Concomitant use with strong CYP3A4 inducers (e.g., rifampin),Kock pouch (ileostomy)
Grapefruit and grapefruit juice increase nicardipine serum concentrations by inhibiting CYP3A4 metabolism. Avoid concurrent use. High-fat meals may increase absorption; take consistently with regard to meals. Alcohol may enhance hypotensive effects; limit intake.
Grapefruit juice increases nifedipine levels via CYP3A4 inhibition; avoid consumption. High-fat meals may delay absorption but do not alter overall exposure. Avoid alcohol as it can exacerbate vasodilation and hypotension.
Nifedipine, the active ingredient in Cardene SR, is classified as FDA Pregnancy Category C. There are no adequate and well-controlled studies in pregnant women. In animal studies, nifedipine has been shown to cause embryotoxicity, placentotoxicity, and fetotoxicity at doses several times the maximum recommended human dose. First trimester: Risk cannot be ruled out; potential for teratogenic effects based on animal data. Second and third trimesters: May cause maternal hypotension and fetal distress due to placental hypoperfusion; use only if benefit outweighs risk. Case reports of fetal distress, perinatal asphyxia, and cesarean delivery associated with use in preterm labor.
Teratogenic effects not established; first trimester: no data in humans, animal studies show no teratogenicity; second and third trimesters: risk of fetal hypoxia, intrauterine growth restriction (IUGR), and oligohydramnios; may cause neonatal hypotension, bradycardia, and hypoglycemia if used near term. Contraindicated in pregnancy for hypertension; use only if benefit outweighs risk (e.g., tocolysis).
Nifedipine is excreted into human breast milk. The milk-to-plasma ratio (M/P) is approximately 1.0. Limited data suggest infant doses are low (less than 5% of maternal weight-adjusted dose). However, due to potential for adverse effects in infants (e.g., hypotension), caution is advised. Use only if clearly needed and monitor infant for bradycardia and hypotension.
Nifedipine excreted into breast milk; M/P ratio approximately 0.42-0.77; limited human data; no adverse effects reported in infants; use with caution during breastfeeding.
Pregnancy does not necessitate routine dose adjustment of oral nifedipine. However, due to increased plasma volume and clearance in pregnancy, lower doses may be effective for hypertension. For tocolysis (off-label), dosing regimens vary (e.g., 10-20 mg oral immediate-release every 4-6 hours). Monitor for hypotension; dose should be individualized based on blood pressure response.
Plasma clearance may increase due to higher volume of distribution and metabolism; no specific dose adjustment recommended; titrate based on maternal blood pressure and response; avoid around labor due to tocolytic effect.
CARDENE SR (nicardipine) is a dihydropyridine calcium channel blocker used for hypertension. Avoid in advanced aortic stenosis due to risk of reduced coronary perfusion. Monitor for peripheral edema, especially in elderly. Use caution in heart failure with reduced ejection fraction due to negative inotropic effects (though less than verapamil). May increase cyclosporine levels; monitor levels. For IV use (not SR), titrate rapidly for hypertensive emergency. Do not crush or chew SR capsules.
AFEDITAB CR is a controlled-release formulation of nifedipine, a dihydropyridine calcium channel blocker. Avoid grapefruit juice as it inhibits CYP3A4 metabolism, increasing nifedipine levels. Use cautiously in patients with aortic stenosis or left ventricular dysfunction due to risk of hypotension. Do not crush or chew tablets; intact shell may appear in stool.
Take exactly as prescribed, usually twice daily. Swallow SR capsules whole; do not crush or chew.,Avoid grapefruit and grapefruit juice as they can increase drug levels and side effects.,May cause dizziness or lightheadedness; avoid driving until you know how you react. Rise slowly from sitting or lying.,Notify your doctor if you experience swelling in ankles or feet, rapid heartbeat, or shortness of breath.,Do not stop abruptly; sudden withdrawal may worsen chest pain or blood pressure.,Keep a daily blood pressure log to track effectiveness.
Swallow the tablet whole; do not crush, chew, or break it.,Avoid grapefruit juice while taking this medication.,Do not discontinue abruptly; taper under medical supervision.,Report symptoms of hypotension like dizziness or fainting.,Limit alcohol intake as it may worsen side effects.,Monitor for fluid retention (ankle swelling) and notify doctor if worsening.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about CARDENE SR vs AFEDITAB CR, answered by our medical review team.
CARDENE SR is a Calcium Channel Blocker that works by Nicardipine is a dihydropyridine calcium channel blocker that inhibits the transmembrane influx of calcium ions into vascular smooth muscle and cardiac muscle. It produces relaxation of coronary vascular smooth muscle and dilation of coronary arteries, and also dilates peripheral arteries, reducing systemic vascular resistance and blood pressure.. AFEDITAB CR is a Calcium Channel Blocker that works by Nifedipine is a dihydropyridine calcium channel blocker that inhibits the influx of calcium ions through L-type channels in vascular smooth muscle and cardiac muscle, leading to vasodilation and reduced myocardial contractility.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between CARDENE SR and AFEDITAB CR depend on the specific clinical indication. These are both Calcium Channel Blocker agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of CARDENE SR is: Initial: 30 mg orally twice daily (SR capsules). Titrate up to 60 mg twice daily. Usual maintenance: 30-60 mg twice daily.. The standard adult dose of AFEDITAB CR is: 30-60 mg orally once daily, extended-release; maximum 90 mg/day.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between CARDENE SR and AFEDITAB CR in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. CARDENE SR is classified as Category C. Nifedipine, the active ingredient in Cardene SR, is classified as FDA Pregnancy Category C. There are no adequate and well-controlled studies in pregnant women. In animal studies, . AFEDITAB CR is classified as Category C. Teratogenic effects not established; first trimester: no data in humans, animal studies show no teratogenicity; second and third trimesters: risk of fetal hypoxia, intrauterine gro. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.